Group 1 - The company has received approval for a new veterinary drug, Methylprednisolone Tablets (for dogs), classified as a Category V new veterinary drug by the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] - The new drug is developed by Zhejiang Haizheng Animal Health Products Co., Ltd. in collaboration with seven other companies, and is intended for the treatment of inflammatory and allergic diseases in dogs [1] - The drug is indicated for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation of the eyes/ears, among other steroid-responsive inflammatory/allergic diseases [1] Group 2 - The registration application for the new veterinary drug was submitted in October 2024, and the product is now ready for production and market launch pending the approval of the veterinary product number [1] - Currently, the company has not been able to obtain specific sales revenue data for similar products from other companies through public channels [2]

Core Viewpoint - Haizheng Pharmaceutical (600267) announced that its subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the new veterinary drug registration certificate for Nirocoxib Chewable Tablets, officially classified as a Class II new veterinary drug [1] Group 1 - The new veterinary drug, Nirocoxib Chewable Tablets, is intended for alleviating pain and inflammation caused by canine osteoarthritis and clinical surgeries [1] - The registration application for Nirocoxib Chewable Tablets was submitted in June 2022, and it was processed by the Ministry of Agriculture and Rural Affairs along with other entities [1] - The product is now ready for production and will be launched once it obtains the veterinary product approval number, but it is not expected to have a significant impact on the company's performance in the short term [1]